<?xml version="1.0" encoding="UTF-8"?>
<ref id="B120-pharmaceuticals-13-00096">
 <label>120.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Madrid</surname>
    <given-names>P.B.</given-names>
   </name>
   <name>
    <surname>Panchal</surname>
    <given-names>R.G.</given-names>
   </name>
   <name>
    <surname>Warren</surname>
    <given-names>T.K.</given-names>
   </name>
   <name>
    <surname>Shurtleff</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>Endsley</surname>
    <given-names>A.N.</given-names>
   </name>
   <name>
    <surname>Green</surname>
    <given-names>C.E.</given-names>
   </name>
   <name>
    <surname>Kolokoltsov</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Davey</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Manger</surname>
    <given-names>I.D.</given-names>
   </name>
   <name>
    <surname>Gilfillan</surname>
    <given-names>L.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Evaluation of Ebola virus inhibitors for drug repurposing</article-title>
  <source>ACS Infect. Dis.</source>
  <year>2015</year>
  <volume>1</volume>
  <fpage>317</fpage>
  <lpage>326</lpage>
  <pub-id pub-id-type="doi">10.1021/acsinfecdis.5b00030</pub-id>
  <?supplied-pmid 27622822?>
  <pub-id pub-id-type="pmid">27622822</pub-id>
 </element-citation>
</ref>
